Pharmacokinetic Study of Fluconazole in Premature Infants
Overview
The purpose of this study is to investigate the pharmacokinetics of fluconazole which is used as prophylaxis of invasive fungal infection in premature infants.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Basic Science
- Masking: None (Open Label)
- Study Primary Completion Date: October 2014
Interventions
- Drug: Fluconazole
- Prophylactic fluconazole administration in VLBW infants
Arms, Groups and Cohorts
- Experimental: Population PK
Clinical Trial Outcome Measures
Primary Measures
- drug level of fluconazole
- Time Frame: 30min later, 10-12hr later, at routine lab with interval of 1week
- four times drug level after 3th dose
Participating in This Clinical Trial
Inclusion Criteria
- very low birth weight infant (birth weight < 1,500 g) who were admitted to the NICU before day 3 of life – Informed consent from the parents Exclusion Criteria:
- Major congenital anomaly – Expired within 72 hours of life – Liver failure (AST or ALT levels with three times the upper limit of the range of normal values or higher) – Proven congenital or intrauterine fungal infection
Gender Eligibility: All
Minimum Age: N/A
Maximum Age: 4 Weeks
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Seoul National University Hospital
- Provider of Information About this Clinical Study
- Principal Investigator: Han-Suk Kim, Professor – Seoul National University Hospital
- Overall Official(s)
- Han-Suk Kim, MD, PhD, Principal Investigator, Seoul National University Hospital
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.